Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isothiafludine
- Development stage
- Unknown
- Lead developer
- Haihe
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Isothiafludine (NZ-4) is a small molecule capsid assembly modulator (CpAM) developed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, in collaboration with Ningbo Nuoze Pharmaceutical for the treatment of chronic hepatitis B (CHB). Unlike traditional nucleos(t)ide analogues that target the viral polymerase, isothiafludine acts as a non-nucleoside inhibitor that binds to the Hepatitis B virus core protein (HBcAg). This binding interferes with the protein-protein interactions required for the assembly of the viral nucleocapsid, leading to the formation of empty or aberrant capsids and preventing the encapsidation of pregenomic RNA (pgRNA). By disrupting these critical steps in the viral life cycle, isothiafludine aims to reduce viral replication and potentially contribute to a functional cure for HBV. It has been evaluated in Phase 1 and Phase 2 clinical trials in China.
- Other names
- Isothiafludine
02
Targets
HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on isothiafludine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isothiafludine.